Sepsis/Locked-In/Stone Man Syndromes: Combating India and the World Through AI-Driven Next-Generation Biosensors And 3d Structural Fingerprinting for Pathogen Detection, Tay-Sachs Disease, Lesch-Nyhan Syndrome, and Metabolic Disorders

Yash Srivastav[1*], Shivani Singh[1], Vivek Kumar[1], Brijesh Kumar Pal[1], Kamini Prajapati[1], Amita Singh[1], Kumar Sandeep[1]

[1]D.K.R.R Pharmacy College, Amberpur, Sitapur, Uttar Pradesh, India. 261303

***Corresponding Author E-mail: yashsrv.108@gmail.com**

Abstract:

This paper reviews various complex diseases such as sepsis, Locked-in Syndrome, Fibrodysplasia Ossificans Progressiva (Stone Man Syndrome), Tay-Sachs disease, Lesch-Nyhan syndrome, and metabolic disorders. Diagnosis and treatment of these medical issues pose significant challenges in healthcare settings because of limitations associated with traditional methods used by clinicians. However, the latest advances in areas such as artificial intelligence (AI), next-generation biosensors, molecular diagnostics, genome sequencing, and 3D structural fingerprinting have brought about major breakthroughs in the process of disease detection, monitoring, and personalized treatment. First, the paper focuses on the application of AI-assisted biosensors in the process of pathogen detection, sepsis diagnosis, and monitoring of patients' health condition in real-time. Moreover, the paper addresses the use of AI, 3D structural fingerprinting, and precision medicine in studying genetics, brain functioning, and metabolic diseases. Finally, the paper discusses the possibility of using AI-powered communication technologies as a tool for helping people suffering from Locked-in Syndrome and innovative techniques used in genetic screening of Tay-Sachs disease, Lesch-Nyhan syndrome, and Stone Man Syndrome. It can be argued that all these technologies allow improving the process of diagnosing these diseases, implementing early interventions, and offering patients individualized treatments, thus eliminating reliance on traditional methods of detecting problems with patients' health.

Keywords: Artificial Intelligence, Next-Generation Biosensors, Sepsis, 3D Structural Fingerprinting, Precision Medicine, Pathogen Detection, Tay-Sachs Disease, Lesch-Nyhan Syndrome.

Received: Feb. 01, 2026 **Revised:** March 21, 2026 **Accepted:** April 19, 2026 **Published:** June 25, 2026

DOI: https://doi.org/10.64474/3139-2741.Vol2.Issue1.6

https://fmbc.nknpub.com/1/issue/archive

1. INTRODUCTION

Artificial intelligence (AI) and biosensor technology, along with molecular diagnostics and bioinformatics tools, have revolutionized healthcare[1]. There has been a tremendous amount of research work done which has opened up novel ways for detecting and treating diseases that were difficult to diagnose and manage before. Sepsis, Locked-in syndrome, fibrodysplasia ossificans progressiva (stone man syndrome), Tay-Sachs disease, Lesch-Nyhan syndrome, as well as many other rare and difficult-to-diagnose diseases have proven to be major healthcare problems because of their rarity, difficulty in diagnosis, and morbidity rates. However, with the application of AI-based diagnostic systems, biosensors, and novel molecular techniques, there is now more hope for finding solutions to these diseases.

Figure 1: Stone Man Syndrome[2]

Traditional methods of disease diagnosis, especially culture-based detection of pathogens, are often associated with long processing times and do not allow for a prompt diagnosis needed to make decisions regarding further patient treatment. This is also common for diseases that have rare genetic or neurological features due to lack of disease recognition and symptoms overlap and inability to get access to novel diagnostic tools. Modern technologies that are gaining popularity include 3D fingerprint structure, genomic sequencing, biomarkers assisted by artificial intelligence, wearable devices, and other technological solutions.

1.1 Background Information and Context

Sepsis is still one of the main causes of death across the world and necessitates prompt diagnosis and therapy to avoid fatal complications. Just like other rare conditions like Locked-in syndrome, Stone Man syndrome, Tay-Sachs disease, and Lesch-Nyhan syndrome, the rare conditions have complicated mechanisms and limited therapeutic options[3]. The conventional method of diagnosing rare diseases involves laborious processes such as lab tests, imaging procedures, and genetic testing which are cumbersome and expensive in many medical facilities. There have been innovations within the areas of artificial intelligence biosensors, molecular diagnostics, and bioinformatics which are helping in the rapid diagnosis and monitoring of patients. Additionally, 3D structure fingerprinting is gaining popularity in the analysis of biological structures, genetic mutations, and molecular characteristics of diseases.

1.2 Objectives of the Review

The primary objectives of this review are:

- To examine the role of AI-driven next-generation biosensors in the rapid detection, diagnosis, and monitoring of sepsis and other complex human diseases.
- To evaluate emerging culture-independent pathogen detection technologies, including genomic sequencing, proteomic fingerprinting, CRISPR-based diagnostics, and AI-assisted molecular platforms.
- To explore the applications of 3D structural fingerprinting and precision medicine in understanding disease mechanisms, genetic mutations, and personalized therapeutic strategies.
- To assess the contribution of advanced diagnostic technologies in the management of Locked-in Syndrome, Stone Man Syndrome (Fibrodysplasia Ossificans Progressiva), Tay-Sachs disease, Lesch-Nyhan syndrome, and metabolic disorders.
- To identify current challenges, research gaps, and future directions for integrating artificial intelligence, biosensors, and precision medicine technologies into global healthcare systems.

1.3 Importance of the Topic

The importance of this topic is based on the increasing necessity for rapid, reliable, and effective diagnostic tools that can deal not only with common threats but with rare genetic disorders. Inadequate diagnostics is one of the main reasons for negative results in cases of sepsis or complicated neurological or metabolic disorders[4]. AI-powered biosensors and modern techniques of molecular diagnostics will allow reducing delays in making diagnoses, improving treatment methods, and increasing chances of survival for patients. Furthermore, the use of personalized medicine practices, based on 3D structural fingerprinting and genome-based analyses, will contribute to providing personalized treatment plans for each patient individually. In connection with the widespread adoption of digitalization by modern healthcare systems all over the world, it is crucial to understand the implications that the development of such techniques may bring about in clinical practice.

2. AI-DRIVEN BIOSENSORS AND ADVANCED PATHOGEN DETECTION TECHNOLOGIES

AI-based biosensors and culture-independent diagnostics tools are transforming the diagnosis of infectious diseases by making it possible to detect biomarkers and pathogens with speed, precision, and in real time[5]. This technology makes sepsis diagnosis easier, improves medical decision-making, minimizes reliance on culture-based techniques, and facilitates personalized medicine.

2.1 AI-Driven Next-Generation Biosensors

Biosensors are sophisticated instruments that measure biological, chemical, or physiological indicators to provide output values that are useful in diagnostics and analysis. Advancements made in the field of biosensors have made use of technologies such as artificial intelligence, nanotechnology, microfluidics, cloud computing, and machine learning techniques to improve diagnostic efficiency. Next-generation biosensors enable early detection of disease biomarkers with high sensitivity and in real time, making them indispensable in today's medical world.



Figure 2: Biosensors[6]

<u>**Methodologies**</u>

Some recent biosensor-based human centered experiments that have been used include:

- Electrochemical biosensors
- Optical biosensors

- Wearable biosensors
- Microfluidic analysis platforms
- Biosensor systems assisted by Artificial Intelligence for processing signal information

In combination with such biosensors, advanced machine learning algorithms that are able to analyze large volumes of data and distinguish disease marker signatures can be used.

Key Findings

According to recent studies, AI-enhanced biosensors have been able to detect complex biomarker signatures which may go undetected using conventional lab tests[7]. The integration of biosensing technology with AI has not only helped increase precision in diagnoses but has also minimized time while allowing for real-time monitoring of the patient's health status.

Strengths

- Speed of diagnosis in real-time
- Good analytical sensitivity and specificity
- Application at the point-of-care
- Less dependency on central laboratories
- Monitoring ability of patients continuously
- An option for personalized healthcare

Weaknesses

- Extremely high costs involved in development and deployment
- Sample size requirement for proper machine learning
- Interoperability of the data used in the algorithm
- Ethical and regulatory issues with using patient information
- Necessity of extensive clinical validation

2.2 AI Biosensors for Sepsis Detection

Sepsis is a critical illness that arises due to an immune system malfunction that leads to the development of an infection within the body and has continued to be among the major causes of mortality globally. Sepsis develops very quickly and is capable of inducing multisystem organ failure if it is not timely diagnosed and addressed. Timely diagnosis plays a very important role since the patient's survival chances become compromised with every passing hour after onset. The standard tests employed involve the use of blood culture.

Recent Research

The following recent studies from human medicine have involved the application of AI-assisted biosensors that can monitor important sepsis-related biomarkers like:

- Procalcitonin (PCT)
- C-reactive protein (CRP)
- Interleukin-6 (IL-6)
- Lactate
- Circulating microbial biomarkers

Biomarker combination analysis has been employed using machine learning algorithms instead of single-biomarker analysis. Multi-biomarker analysis is much more effective in predicting patient outcomes. Multiple wearables and POCT biosensor systems have also been engineered to enable constant patient monitoring[8].

Key Findings

Biosensors that rely on AI have shown significant benefits over traditional diagnostics. It has been reported that such sensors will help in early sepsis diagnosis, aid in better patient risk stratification, and facilitate more informed therapy selection for individuals. Continuous monitoring of biomarker levels will help evaluate treatment response and identify deteriorating conditions early.

Critical Evaluation

However, some limitations still apply despite the positive results. The levels of biomarker expression might vary from one individual to another based on age, underlying diseases, genetic makeup, and extent of illness. Besides, variations in health system and patient profile could affect the applicability of biosensors to diagnosing diseases through predictive models. Thus, multicenter research is required before application becomes feasible[9].

2.3 Bypassing Culture-Based Pathogen Detection

Culture-based diagnostics relying on traditional culture procedures have always been viewed as the gold standard when detecting pathogens causing an infection. Nevertheless, there are a number of drawbacks associated with these diagnostic techniques. First of all, culturing pathogens is a time-consuming procedure that takes at least 24-72 hours before delivering the final results. Secondly, a successful detection of the disease-causing organisms implies the presence of living cultures and laboratory equipment.

Limitations include the following:

- Long duration (24 to 72 hours, etc.)
- The need for microbiology labs
- Microbial samples must be viable
- Loss of sensitivity after antibiotic administration
- Problems with delayed intervention

Emerging Alternatives

Advancements in technology have seen the development of novel culture-free methods of diagnosing illnesses[10]. Clinical applications for humans have seen the testing of many potential methods of diagnosing illnesses such as:

- Genomic Sequencing
- Protein Fingerprinting
- Molecular diagnostics assisted by AI
- CRISPR detection systems
- Biosensors utilizing microfluidics
- Pathogen digital surveillance systems

The new methods can detect illness-causing organisms by detecting their genetic material, protein, metabolites, or host response markers without having to culture them first[11].

Findings

There is increasing evidence that culture-independent techniques used in diagnostics are effective in cutting down the delay in diagnosing infectious diseases and enhancing the precision of detecting pathogens[12]. The use of artificial intelligence in analyzing biological data and differentiating among bacterial, viral, and fungal infections will be efficient. In addition, CRISPR-based pathogen detection technology and microfluidic biosensors are capable of fast and accurate pathogen detection. This new technological approach can change how infectious diseases are managed by ensuring early diagnosis and precise treatment.

3. AI-DRIVEN DIAGNOSTIC TECHNOLOGIES, 3D STRUCTURAL FINGERPRINTING, AND PRECISION MEDICINE APPLICATIONS

Technologies that are revolutionizing the diagnosis and treatment of infections, nervous system-related diseases, genetic abnormalities, and metabolic disorders include AI-enabled biosensors, 3D structural fingerprinting, genomics, and digital biomarkers[13]. They allow for timely, precise, and highly personalized care delivery through accurate and efficient disease identification, enhanced monitoring, precision-based medicine, and positive health outcomes.

3D Structural Fingerprinting and Precision Medicine

Three-dimensional structural fingerprinting refers to a sophisticated biomedical technique whereby advanced technologies such as molecular imaging, artificial intelligence, molecular profiling, and computer modeling are used to create intricate images of biological structures[14]. It offers a unique opportunity for scientists and doctors to view biological structures such as proteins, genes, and even cellular interactions in three dimensions. In contrast to traditional diagnostic methods that emphasize individual biomarkers, 3D structural fingerprinting considers the impact of complicated biological structures and molecular profiles that can have a significant impact on disease development.

Figure 3: 3D Structural Fingerprinting[15]

Precision medicine utilizes 3D structure fingerprinting in the process of protein structure characterization, detecting genetic mutations, predicting drug-protein interactions, and designing therapies based on individual needs. Genomic analyses have revealed that there are structural alterations in proteins and genes which have an impact on disease development and the patient's response to medications[16]. With this information, medical professionals can generate a personalized profile for a patient and come up with an effective therapy based on their molecular and physiological profile.

- **Locked-in Syndrome and AI-Assisted Communication Technologies**

Locked-in Syndrome (LIS) is an uncommon neurological syndrome that involves paralysis of the voluntary muscle control systems while the person is aware and cognitively functioning. Persons who have been diagnosed with locked-in syndrome cannot speak or move, although they are fully conscious of their environment[17]. Locked-in syndrome can be linked with brainstem damage, stroke, head trauma, and neurodegenerative diseases. A quick and proper diagnosis of LIS is necessary since misdiagnosis could cause the medical practitioners to misjudge the cognitive status and the quality of life of the patient.

Figure 4: Locked-in Syndrome (LIS)[18]

Recent developments in AI and neurotech have brought about an explosion in terms of communication methods available to people diagnosed with Locked-in Syndrome. Clinical research on humans has been carried out on brain-computer interfaces, eye-tracking technology, EEG-based communication systems, and neuro-decoding platforms through AI[19]. The technology allows for communication of brain signals through typing or vocalization in order to communicate with loved ones and other people. Despite the progress made by such devices in terms of improving patients' independence, various obstacles like the high cost, lack of accessibility, and complicated procedures still hinder their wider use.

- **Stone Man Syndrome (Fibrodysplasia Ossificans Progressiva)**

Fibrodysplasia Ossificans Progressiva (FOP), popularly called Stone Man Syndrome, is an uncommon genetic disease involving abnormal bone formation in muscles, tendons, ligaments, and other soft tissues[20]. This disease occurs mainly due to mutations in the ACVR1 gene, responsible for bone development and growth. With time, patients develop limitations in movement as soft tissues begin to ossify into bones. As FOP is very rare and mimics other musculoskeletal diseases, it is often diagnosed incorrectly and, therefore, treated improperly at the early stage.



Figure 5: Fibrodysplasia Ossificans Progressiva[21]

Progress in the technology used for diagnosis has enhanced the ability to detect and track FOP in humans. Genetic tests are the best way to determine ACVR1 mutations, while the use of advanced methods such as CT scan and MRI imaging helps to see bone development abnormalities. The use of AI-supported radiology analysis and 3D modeling can further help identify some minor anatomical issues that might be missed in regular diagnosis tests[22]. The use of these technologies can contribute to early detection and monitoring of FOP as well as assist in devising more personalized treatment approaches to decrease morbidity.

Tay-Sachs Disease and AI-Based Genetic Screening

The Tay-Sachs disease is a rare genetic condition that involves the deterioration of the brain nerves due to the presence of mutations in the HEXA genes, hence the deficiency of the beta-hexosaminidase enzyme[23]. The accumulation of the GM2 gangliosides in the neurons results in the deterioration of neurological functions as well as developmental disabilities. Timely diagnosis of the condition is crucial since it provides opportunities for genetic counseling, planning of pregnancy, and intervention measures. Conventional diagnosis involves the assessment of enzyme activities and genetic profiling.

Advances made in artificial intelligence-based genetic screening methods have greatly improved the process of detection and classification of the Tay-Sachs disease. AI algorithms are able to detect mutations quickly, classify them according to their significance, and determine disease severity from the genetic profile of patients[24]. With the help of next generation sequencing and predictive genetic models, as well as structural mutation mapping, a complete picture regarding the patient's health condition can be created.

Lesch-Nyhan Syndrome

Lesch Nyhan syndrome is a rare congenital disease characterized by genetic defects in the HPRT1 gene, which codes for the enzyme hypoxantine guanine phosphoribosyl transferase (HPRT)[25]. Absence of the enzyme leads to disorders in purine metabolism leading to hyperuricaemia and several neurological and psychological manifestations. Some patients display delayed development, difficulty walking, self-mutilation tendencies, and cognitive disturbances. Diagnosis can be difficult due to the diverse nature of symptoms of this condition, especially in regions where advanced diagnostic facilities are not easily accessible.

With the help of technological innovations, Lesch-Nyhan syndrome can be diagnosed better and managed due to the use of genomic sequencing, metabolomics, and artificial intelligence in diagnosing. In human clinical trials, it has been proven that by using genetic data combined with metabolic markers, one can achieve better results regarding the understanding of the disease[26]. By using artificial intelligence, one is able to correlate the information obtained from genome sequencing and metabolomics and diagnose the condition better.

Metabolic Disorders and Digital Biomarker Platforms

Metabolic diseases refer to a number of genetic and acquired diseases affecting the biochemical processes in the body associated with metabolism and energy production in the body[27]. These diseases include diabetes mellitus, phenylketonuria, lysosomal storage diseases, mitochondrial diseases, and many others. Some metabolic diseases have to be monitored throughout one's life due to the fact that there are certain factors which determine the progression of such diseases, such as genetic predisposition, environment, and lifestyle. Traditional diagnostic procedures involve conducting laboratory tests from time to time.

With the development of digital biomarker systems and artificial intelligence (AI) biosensors, monitoring and managing metabolic disorders have become highly sophisticated processes. Diagnostic wearable devices, metabolic monitoring systems, and predictive models using AI help evaluate physiological and biochemical indicators in real time. They can detect any imbalance in the body and predict the occurrence of complications or disease exacerbations. Clinical studies involving humans have shown that digital biomarker systems help monitor diseases better and make precise diagnoses[28].

4. AI-DRIVEN PRECISION MEDICINE AND PERSONALIZED THERAPEUTIC STRATEGIES

The introduction of artificial intelligence in modern healthcare has facilitated the implementation of precision medicine strategies that emphasize the importance of making patient-specific diagnosis, prognosis, and treatment plans[29]. As opposed to traditional medical treatments, which employ similar methods for treating groups of people, precision medicine takes into account patient-specific data, including genetics, biomarkers, patient histories, and their environment, among others, in the formulation of patient care programs. Artificial intelligence makes it possible for health practitioners to analyze big and complicated datasets in a short while in order to recognize specific disease trends and predict patient outcomes.

The use of the new generation biosensors along with AI technology has greatly contributed to personalized medicine. The new biosensors are capable of measuring continuous data on various parameters, including inflammation, metabolism, and biomarkers of particular diseases. These data are analyzed by AI systems that predict possible scenarios in terms of disease development and the patient's response to treatment as well as possible complications. The example of applying this technique is its use in the treatment of sepsis.

AI-based precision medicine provides various benefits for patients suffering from rare genetic diseases like Tay Sachs disease, Lesch-Nyhan syndrome, and Fibrodysplasia ossificans Progressiva, also known as Stone man syndrome. For example, machine learning technology may be applied for analysis of genomic sequencing information for detection of harmful mutations and their connection with the manifestation of certain diseases. Moreover, 3D structure fingerprinting approaches may be used to gain more information on the processes that occur at molecular and protein levels which will help scientists learn about possible therapies[30].

Although there is great promise in terms of the opportunities that AI-driven precision medicine offers, there are still a number of challenges to overcome. These include data privacy concerns, the need for algorithmic transparency, the validation of findings in a clinical setting, as well as issues associated with health care accessibility. Moreover, in order to combine different data sources, such as genomics, proteomics, medical imaging, and clinical information, significant computational capability will be required. In the future, researchers should look into developing explainable AI techniques as well as promoting interoperability and universal accessibility of advanced diagnostics equipment.

Table 1: Summary of Literature Review on AI-Driven Biosensors, Diagnostics, and Precision Medicine[31]

Author(s) & Year	**Study Focus**	**Key Findings**	**Relevance to Present Review**
Chaudhary et al. (2025)[32]	AI-enhanced nanosensors for advanced biomedical diagnostics	AI-integrated nanosensors improved sensitivity, specificity, and speed of disease detection while enabling real-time biomarker monitoring and personalized healthcare.	Supports the application of AI-driven biosensors for rapid diagnosis, disease monitoring, and precision medicine.

Aldea et al. (2025)[33]	Detection of antibiotic resistance using classical, molecular, bioengineering, and AI-enhanced approaches	AI improved microbial data analysis and accelerated identification of antibiotic-resistant pathogens, enhancing infection management.	Demonstrates the value of AI-assisted pathogen detection and culture-independent diagnostic technologies.
Parvin et al. (2025)[34]	Multimodal AI in biomedicine, diagnostics, and personalized healthcare	Integration of imaging, genomic, molecular, and clinical data improved disease prediction, diagnostic accuracy, and treatment planning.	Highlights the role of AI and precision medicine in personalized healthcare and advanced diagnostics.
Baskaran et al. (2025)[35]	Applications of AI and machine learning in microbiome and colorectal cancer research	AI-based tools enhanced microbial signature identification, diagnostic assessment, prognostic evaluation, and personalized treatment approaches.	Supports the use of AI-driven analytics for disease prediction, biomarker discovery, and precision medicine applications.
Dixit et al. (2024)[36]	Analytical biotechnology tools and applications in healthcare research	Advanced biotechnological techniques improved disease diagnosis, biomarker analysis, and translational research outcomes.	Provides foundational support for integrating analytical biotechnology with AI-driven diagnostic platforms and biosensor technologies.

5. DISCUSSION

The use of artificial intelligence, new-age biosensors, molecular diagnostics, and 3D structural fingerprinting in healthcare has revolutionized the medical world, allowing quick and easy diagnosis and personalized treatments for infections, neurodegenerative diseases, genetic diseases, and metabolic disorders. Nevertheless, more research is required in this area in order to deal with issues such as validation, privacy, and accessibility[37].

5.1 Interpretation and Analysis of Findings

The results analyzed in this study prove the emergence of AI, new-generation biosensors, 3D structural fingerprinting, and molecular diagnostics as powerful tools in the diagnosis and treatment of infections, neurodegenerative diseases, rare genetic disorders, and metabolic syndromes. AI-powered biosensors have proven to be highly effective in performing fast and accurate detection of biomarkers especially in severe medical cases like sepsis when prompt response can save lives[38]. Culture-independent pathogen identification methods based on genome sequencing, proteomics, and CRISPR techniques have shortened diagnostic processes and increased efficiency in detecting pathogens. In addition, AI combined with structural and genomic analyses has been instrumental in enhancing the application of precision medicine practices through personalized diagnosis and treatment of rare diseases such as Tay-Sachs disease, Lesch-Nyhan syndrome, and Fibrodysplasia Ossificans Progressiva.

5.2 Implications and Significance

The increasing use of artificial intelligence in diagnostic equipment is relevant for both the clinical practice and the global healthcare system. Quick diagnostics using biosensors may help detect diseases early on, shorten stays at the hospitals, find more efficient treatments, and achieve better results for patients overall. With regard to sepsis treatment, real-time monitoring systems might become an element that will help decrease the mortality rate due to quick interventions[39]. What is more, communication solutions with the help of AI have enabled enhancing the quality of life for people suffering from locked-in syndrome, whereas genome and structure fingerprints became a tool used to diagnose genetic conditions. All of the advancements mentioned above are extremely important for the field of precision medicine since now physicians can create personalized treatment plans based on specific traits of each organism.

5.3 Research Gaps and Future Directions

However, despite considerable advances made by these emerging technologies, there is still plenty of room for improvement in order to incorporate them into clinical practice. The first problem concerns the need for adequate data sets used for testing many AI-powered diagnostic tools, while existing research frequently employs small numbers of patients in particular settings. Privacy concerns, the transparency of machine learning algorithms, system interoperability, regulatory requirements, as well as affordability of healthcare services, should also be addressed in the future. Specifically, additional large-scale human clinical trials conducted in multiple centers are required to test diagnostics in various settings[40]. Explaining AI algorithms, combining multi-omics analysis platforms, designing advanced wearables and digital health care systems, among other directions of research, might further improve clinical outcomes in the future.

6. CONCLUSION

This review emphasizes the importance of artificial intelligence, next-generation biosensors, molecular diagnostics, 3D structural fingerprinting, and precision medicine in overcoming the limitations that arise due to sepsis, Locked-in Syndrome, Fibrodysplasia Ossificans Progressiva (Stone Man Syndrome), Tay-Sachs disease, Lesch-Nyhan syndrome, and various metabolic disorders. These breakthrough technologies have proven to be highly effective when it comes to pathogen identification, accurate diagnosis of diseases, real-time patient monitoring, personalized therapy, and decision-making in the field of healthcare. AI-based biosensors and culture-free diagnostics have provided alternative ways to detect pathogens and diagnose diseases. Meanwhile, advances in the fields of neurotechnology, genetics, genomic analysis, and digital biomarkers have made it possible to tackle rare diseases such as Locked-in Syndrome and various other neurological and metabolic disorders. Although great success has been achieved in terms of research and development of these technologies, several challenges should also be mentioned. For example, the process of validating biosensors can be problematic and costly, which raises issues of standardization, accessibility, and affordability. Nevertheless, continued efforts and innovations in the area of artificial intelligence and biotechnology will be vital for successful adoption of these technologies in routine medical practice. It is crucial to ensure the responsible use of these technologies and their benefits for patients and society as a whole. In general, this area promises revolutionary improvements in the healthcare system not only in India but also around the world.

REFERENCES

1. Ejjineni, P., Degala, R. P., Vara, S., Gokavarapu, M., & Burugu, P. (2025). A Comprehensive Review on Stone Man Syndrome. Journal of Pharma Insights and Research, 3(1), 219-227.
2. Shah, Z. A., Rausch, S., Arif, U., & El Yafawi, B. (2019). Fibrodysplasia ossificans progressiva (stone man syndrome): a case report. Journal of Medical Case Reports, 13(1), 364.
3. Sidana, S., Kaur, H., Sugandha, G. S., & Goyal, T. (2025). A rare encounter: A case report of fibrodysplasia ossificans progressive (Stone Man syndrome) in an adolescent. J Clin Images Med Case Rep, 6(4), 3549.
4. Boyd, C., Wood, K., Whitaker, D., & Assimos, D. G. (2018). The influence of metabolic syndrome and its components on the development of nephrolithiasis. Asian journal of urology, 5(4), 215-222.
5. Johnson, R. J., Perez-Pozo, S. E., Lillo, J. L., Grases, F., Schold, J. D., Kuwabara, M., ... & Lanaspa, M. A. (2018). Fructose increases risk for kidney stones: potential role in metabolic syndrome and heat stress. BMC nephrology, 19(1), 315.
6. Carbone, A., Al Salhi, Y., Tasca, A., Palleschi, G., Fuschi, A., De Nunzio, C., ... & Pastore, A. L. (2018). Obesity and kidney stone disease. A systematic review. Minerva urologica e nefrologica, 393-400.
7. Singh, P., Harris, P. C., Sas, D. J., & Lieske, J. C. (2022). The genetics of kidney stone disease and nephrocalcinosis. Nature Reviews Nephrology, 18(4), 224-240.

8. Southern, J. B., Higgins, A. M., Young, A. J., Kost, K. A., Schreiter, B. R., Clifton, M., ... & Garg, T. (2019). Risk factors for postoperative fever and systemic inflammatory response syndrome after ureteroscopy for stone disease. Journal of endourology, 33(7), 516-522.
9. Chang, C. W., Ke, H. L., Lee, J. I., Lee, Y. C., Jhan, J. H., Wang, H. S., ... & Geng, J. H. (2021). Metabolic syndrome increases the risk of kidney stone disease: a cross-sectional and longitudinal cohort study. Journal of personalized medicine, 11(11), 1154.
10. Jain, R., Kochar, M., Dubey, M. K., Sharma, S. S., Yang, W., & Cahill, D. (2025). Advancing Diagnostics for Xanthomonas oryzae pv. oryzae: Challenges and Future Directions. ACS Agricultural Science & Technology, 5(8), 1529-1548.
11. Bhowmik, D., Rickard, J. J. S., Jelinek, R., & Oppenheimer, P. G. (2025). Resilient sustainable current and emerging technologies for foodborne pathogen detection. Sustainable Food Technology, 3(1), 10-31.
12. Subburaj, S., Liu, C., & Xu, T. (2025). Emerging trends in AI-integrated optical biosensors for point-of-care diagnostics: current status and future prospects. Chemical Communications.
13. Khan, H., Jan, Z., Ullah, I., Alwabli, A., Alharbi, F., Habib, S., ... & Koo, J. (2024). A deep dive into AI integration and advanced nanobiosensor technologies for enhanced bacterial infection monitoring. Nanotechnology Reviews, 13(1), 20240056.
14. Yadav, A., & Yadav, K. (2025). Portable solutions for plant pathogen diagnostics: development, usage, and future potential. Frontiers in Microbiology, 16, 1516723.
15. Oon, Y. L., Oon, Y. S., Ayaz, M., Deng, M., Li, L., & Song, K. (2023). Waterborne pathogens detection technologies: advances, challenges, and future perspectives. Frontiers in Microbiology, 14, 1286923.
16. Lawal, O. P., Opara, I. J., Ayo-Ige, A., Eboh, N. A., Cos-Ibe, U., Forson, K. A. A. M., ... & Forson, K. (2025). Artificial Intelligence-Integrated Biosensors for Antimicrobial Resistance Detection and Surveillance: A Review and Future Perspectives for Global Biosecurity. Cureus, 17(11).
17. Singhal, C., Chatterjee, S., Gupta, S., Shamsi, S., Sharma, C., Gautam, H., & Chaudhuri, S. (2026). Sepsis Diagnostics via Biosensors: Engineering Platforms, Artificial Intelligence Integration, and Clinical Translation. ACS sensors, 11(3), 1756-1773.
18. Banicod, R. J. S., Tabassum, N., Jo, D. M., Javaid, A., Kim, Y. M., & Khan, F. (2025). Integration of artificial intelligence in biosensors for enhanced detection of foodborne pathogens. Biosensors, 15(10), 690.
19. Chansi, Wani, B. G., Mir, M., & Basu, T. (2026). AI-Assisted Biosensors for Environmental Pollutant Monitoring. In Biosensors for Environmental Analysis and Monitoring: Concepts, Applications and Challenges (pp. 113-151). Cham: Springer Nature Switzerland.

20. Tabassum, M. M., Vasimalla, Y., Singh, R., & Kumar, S. (2026). Advanced Optical Sensing Techniques for Biomolecular Detection in the Human Body: Principles, Technologies, and Clinical Perspectives. The Chemical Record, e202500251.
21. Pandhi, S., Kumari, N., Jain, A., & Sharma, V. (2025). Emerging technologies in food safety: AI-powered, nano-enabled, and biosensor-based strategies for rapid contaminant detection. Food Analytical Methods, 18(9), 2010-2024.
22. Abidharini, J. D., Manoj, M., Arthi, G., Ramya, R., Kumar, A. S., Robert, A. A., ... & Anand, A. V. (2025). AI Technologies and Molecular Diagnostics for Managing Infectious Diseases. In AI and Precision Medicine in Infectious Disease Management (pp. 118-136). CRC Press.
23. Radhika, J. M., Ajayan, J., Bhattacharya, S., & Sreejith, S. (2026). AI and IoT Integration in Biomolecular Sensing Systems. Biocompatible Nanomaterials for Smart Sensors: Environmental and Biomedical Applications, 121-138.
24. Umapathi, K. (2025). Non-invasive biochemical sensing with AI-driven analytics: a comprehensive review of technologies, applications, and future directions. Analytical Methods.
25. Chen, J. T. (Ed.). (2025). AI and Precision Medicine in Infectious Disease Management. CRC Press.
26. Mohanan, P. V. (Ed.). (2025). Artificial intelligence and biological sciences. CRC Press, Taylor & Francis Group.
27. Todorović, A., Bobić, K., & Drakulić, D. (2023). Innovative and multidisciplinary approaches in detecting biological agents using contemporary technologies. Archibald Reiss Days, 13.
28. Alves, E., Gurupadayya, B. M., & Prabhakaran, P. (2025). Next-Generation Miniaturized Separation Platforms: Converging Detection, Automation, and Sustainable Design for Intelligent Analytical Science. Critical Reviews in Analytical Chemistry, 1-50.
29. Chaudhary, D., Gupta, S., Usha, & Kaushal, A. (2025). AI-Enhanced Nanosensors for Advanced Diagnostics. In Nanosensors in Biomedical Technology (pp. 335-348). Singapore: Springer Nature Singapore.
30. Aldea, A. C., Diguță, F. C., Presacan, O., Voaideș, C., Toma, R. C., & Matei, F. (2025). Detecting antibiotic resistance: classical, molecular, advanced bioengineering, and AI-enhanced approaches. Frontiers in Microbiology, 16, 1673343.
31. Alves, E., Gurupadayya, B. M., & Prabhakaran, P. (2025). Next-Generation Miniaturized Separation Platforms: Converging Detection, Automation, and Sustainable Design for Intelligent Analytical Science. Critical Reviews in Analytical Chemistry, 1-50.
32. Chaudhary, D., Gupta, S., Usha, & Kaushal, A. (2025). AI-Enhanced Nanosensors for Advanced Diagnostics. In Nanosensors in Biomedical Technology (pp. 335-348). Singapore: Springer Nature Singapore.

33. Aldea, A. C., Diguță, F. C., Presacan, O., Voaideș, C., Toma, R. C., & Matei, F. (2025). Detecting antibiotic resistance: classical, molecular, advanced bioengineering, and AI-enhanced approaches. Frontiers in Microbiology, 16, 1673343.
34. Parvin, N., Joo, S. W., Jung, J. H., & Mandal, T. K. (2025). Multimodal AI in biomedicine: pioneering the future of biomaterials, diagnostics, and personalized healthcare. Nanomaterials, 15(12), 895.
35. Baskaran, N., Venkatesh, M., Soundararajan, S., Ranjan, J., Islam, A., Hussain, M. S., ... & Ashique, S. (2025). Applications of Artificial Intelligence and Machine Learning in Microbiome and Colorectal Cancer Research: Diagnostic Advances, Prognostic Tools, and Forensic Implications. Current Pharmaceutical Design.
36. Dixit, D., Yadav, P., Yadav, M., & Jha, A. (2024). Chapter-7 Analytical Biotechnology: Tools and Applications. Chief Editor Dr. Harshada Joshi, 167, 135.
37. Ahamed, M. R., Mukherjee, P., Deshpande, P., & RoyChaudhuri, C. (2026). Cutting-Edge Bioanalytical Transducers for Mycotoxin Surveillance: A Review. IEEE Sensors Journal.
38. Nandi, S., Adimule, V., Nesargi, S. S., Hanaji, S., Keri, R., & Barmavatu, P. (2026). Quantum Biosensors in Drug Discovery and Development. Quantum Biosensing in Medical Diagnostics, 205-234.
39. Khanal, S., Sharma, A., Pillai, M., Thakur, P., Tapwal, A., Kumar, V., ... & Kumar, D. (2025). Artificial intelligence-driven innovation in Ganoderma spp.: potentialities of their bioactive compounds as functional foods. Sustainable Food Technology, 3(3), 759-775.
40. Sande, S., & Rajguru, M. (2025). Transforming Medical Microbiology: The Role of Artificial Intelligence. Journal of Pure & Applied Microbiology, 19(3).